CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell Malignancies

Conditions

• Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
• Relapsed or Refractory B-cell Non-hodgkin Lymphoma

Interventions

• BIOLOGICAL: Anti-CD19 Universal CAR-T Cells injection

Sponsor

920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Collaborators

• [object Object]
• [object Object]